"Metformin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
| Descriptor ID |
D008687
|
| MeSH Number(s) |
D02.078.370.141.450
|
| Concept/Terms |
Metformin- Metformin
- Dimethylbiguanidine
- Dimethylguanylguanidine
|
Below are MeSH descriptors whose meaning is more general than "Metformin".
Below are MeSH descriptors whose meaning is more specific than "Metformin".
This graph shows the total number of publications written about "Metformin" by people in this website by year, and whether "Metformin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 1 | 2 |
| 2005 | 1 | 3 | 4 |
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 3 | 2 | 5 |
| 2010 | 8 | 3 | 11 |
| 2011 | 7 | 5 | 12 |
| 2012 | 9 | 7 | 16 |
| 2013 | 5 | 0 | 5 |
| 2014 | 15 | 2 | 17 |
| 2015 | 5 | 4 | 9 |
| 2016 | 7 | 5 | 12 |
| 2017 | 2 | 4 | 6 |
| 2018 | 6 | 4 | 10 |
| 2019 | 9 | 3 | 12 |
| 2020 | 11 | 4 | 15 |
| 2021 | 7 | 4 | 11 |
| 2022 | 4 | 1 | 5 |
| 2023 | 9 | 0 | 9 |
| 2024 | 7 | 1 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Metformin" by people in Profiles.
-
Initiation of metformin in early pregnancy results in fetal bioaccumulation, growth restriction, and renal dysmorphology in a primate model. Am J Obstet Gynecol. 2024 Sep; 231(3):352.e1-352.e16.
-
Long-term combination therapy with metformin and oxymetholone in a Fanconi anemia mouse model. Pediatr Blood Cancer. 2024 Aug; 71(8):e31030.
-
Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes. J Clin Endocrinol Metab. 2024 Apr 19; 109(5):1361-1370.
-
Impact of Insulin Sensitivity and ?-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy. Diabetes Care. 2024 Apr 01; 47(4):571-579.
-
Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy. Am Fam Physician. 2024 04; 109(4):333-342.
-
Lac-Phe mediates the effects of metformin on food intake and body weight. Nat Metab. 2024 Apr; 6(4):659-669.
-
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.
-
Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial. Anticancer Res. 2024 Jan; 44(1):133-137.
-
The Effectiveness of Metformin in Managing Second Generation Antipsychotic-Induced Weight Gain in Children and Adolescents. J Clin Psychiatry. 2023 Dec 20; 85(1).
-
Editorial: Global excellence in natural products for endocrine disorders. Front Endocrinol (Lausanne). 2023; 14:1325355.